Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Neuronasal Inc. has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 2 distinct examiners, meaning each of the 2 pending matters is being reviewed by a different individual. This one-to-one ratio shows a decentralized prosecution workload across the current portfolio. This distribution suggests that the company's pharmaceutical filings are subject to the individual interpretations of 2 different examiners, requiring a highly adaptable prosecution strategy for each application.
The company's matters are spread across 2 distinct art units. With 2 pending office actions, each matter is being processed in a different specialized division of the patent office. This presence in 2 art units indicates that the company's pharmaceutical filings cover distinct technical classifications. The ratio of 2 actions to 2 art units shows that the company's filings are technically diverse, with no consolidation within any single specialized examination group, requiring the company to manage its intellectual property across different technical silos.
DAVID PAUL BOWLES is the busiest examiner for the portfolio, currently handling 1 pending office action. As both distinct examiners are managing exactly 1 action each, the workload is uniform across the 2 pending matters. The management of 2 pending actions in 2 art units reflects the company's current patent activity. This balanced distribution across 2 examiners and 2 art units highlights the varied nature of the company's ongoing research and development efforts in the biotechnology sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BOWLES, DAVID PAUL | 1 | 72.7% | +22.4% |
| LEE, WILLIAM Y | 1 | 47.9% | +34.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18295125 | MAGNETIC RESONANCE SPECTROSCOPY TO CALIBRATE AND SELECT DOSES, FORMULATIONS, AND DEVICES FOR INTRA-NASAL ADMINISTRATION OF N-ACETYLCYSTEINE | LEE, WILLIAM Y | 92d overdue |
| 19418017 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES WITH N-ACETYLCYSTEINE AND GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS | BOWLES, DAVID PAUL | — |
| Art Unit | Apps |
|---|---|
| 1654 | 1 |
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19418017 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES WITH N-ACETYLCYSTEINE AND GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS | BOWLES, DAVID PAUL | 1654 | §103§112DP | Non-Final OA | — | Pending | Dec 12, 2025 |
| 18295125 | MAGNETIC RESONANCE SPECTROSCOPY TO CALIBRATE AND SELECT DOSES, FORMULATIONS, AND DEVICES FOR INTRA-NASAL ADMINISTRATION OF N-ACETYLCYSTEINE | LEE, WILLIAM Y | 1623 | §103DP | Non-Final OA | 92d overdue | Pending | Apr 03, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial